Dx Deals: Abbott Closes Exact Sciences Acquisition, Takes Control of Cologuard Franchise
Biotech giant purchased the company for $21 billion, one of the largest deals in clinical lab history
Author Information
Ron Shinkman
Ron Shinkman is a veteran journalist and editor with more than 20 years of experience in the healthcare business realm. He served as Los Angeles bureau chief of Modern Healthcare and also wrote for the Los Angeles and Orange County Business Journals.
Posts by the Author
FDA Watch: MeMed and NG Biotech Receive FDA Breakthrough Device Designations for Rapid Infection Tests
In both cases, the diagnostic tests report results back within 15 minutes
ADLM Calls on Feds to Regulate AI in the Clinical Lab Sector
But anti-regulatory stance taken by Trump administration could serve as a potential obstacle in the effort
Quest Introduces Myeloma Test That Eliminates the Need for Bone Marrow Biopsies
The flow cytometry assay costs a fraction of traditional invasive bone marrow testing
ClearNote Health Launches Early Detection Test for Pancreatic Cancer
The test offers a 76 percent sensitivity to detection of stage 1 and stage 2 pancreatic cancers
Dx Deals: Labcorp Buys Select Assets of Empire City Laboratories
The national lab giant swiftly merged Empire City’s operations into its own
Diagnostics Pipeline: NeuroQure Launches Test for Early Autism Diagnosis
The skin-based test can be used on children as young as two days old
Overturning of Molecular Test Coverage Denials Varies Widely, According to UCSF Study
Research into independent medical review data in four states show payers’ internal policies affect rates of overturns
Dx Deals: Fulgent Genetics Scores Two Laboratories in a Single Deal
It is acquiring Bako Diagnostics and StrataDx for a combined $55.5 million
FDA Watch: Truvian Health Obtains 10 Additional FDA Clearances for TruVerus Platform
TruVerus is designed to perform a slew of clinical laboratory tests on as few as eight drops of blood
